Last reviewed · How we verify
Femamide (FENALAMIDE)
Femamide (generic name: FENALAMIDE) is a drug. It is currently in Phase 2 development.
Femamide is thought to work by interacting with a specific molecular target to produce a therapeutic effect.
Femamide, also known as Fenalamide, is a small molecule drug with unknown target and drug class. Its commercial status is unclear, and it is not known whether it is patented or generic. The indications for which it is approved are also unknown. Further research is needed to understand its mechanism of action and key safety considerations. As a result, Femamide is not widely recognized in the pharmaceutical industry.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | FENALAMIDE |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
While the exact details of how Femamide works are not well understood, it is believed to bind to a specific protein or receptor in the body, which triggers a series of chemical reactions that ultimately lead to its therapeutic effects. This process can help to modify the body's response to certain conditions, leading to improved health outcomes. However, more research is needed to fully understand the mechanism of action of Femamide.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Femamide CI brief — competitive landscape report
- Femamide updates RSS · CI watch RSS
Frequently asked questions about Femamide
What is Femamide?
How does Femamide work?
What is the generic name of Femamide?
What development phase is Femamide in?
Related
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing